Related Experiment Video
Updated: Jul 31, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Vitamin E therapy in Parkinson's disease.
Marc W Fariss1, Jin-Gang Zhang
1Department of Pharmaceutical Sciences, College of Pharmacy, Washington State University, Pullman, WA 99164-6534, USA. fariss@mail.wsu.edu
Toxicology
|June 25, 2003
Summary
Parkinson's disease (PD) involves mitochondrial oxidative stress. Vitamin E therapy, by enriching mitochondria with d-alpha-tocopherol, may protect against this damage and serve as a potential treatment for PD.
Area of Science:
- Neuroscience
- Toxicology
- Biochemistry
Background:
- Parkinson's disease (PD) etiology is multifactorial, involving environmental toxicants, endogenous compounds, and genetic factors.
- Mitochondrial (mito) oxidative stress and damage in the substantia nigra are implicated in PD pathogenesis and neuronal cell death.
- Targeting mitochondrial protection is crucial for developing effective PD therapies.
Purpose of the Study:
- To review evidence linking environmental toxicants and mitochondrial oxidative stress to PD.
- To discuss the protective role of d-alpha-tocopherol (T) enrichment and vitamin E therapy in PD.
- To present new data supporting mito T enrichment as a cytoprotective mechanism.
Main Methods:
- Review of experimental and clinical evidence on environmental toxicants and PD.
- Analysis of the role of mitochondrial oxidative stress in PD.
- Presentation of new experimental data on mito T enrichment and cytoprotection.
Main Results:
- Environmental and endogenous factors contribute to PD via mitochondrial oxidative stress.
- Mitochondrial enrichment with d-alpha-tocopherol (T) is critical for cytoprotection against oxidative stress.
- New experimental data support the protective role of mito T enrichment.
Conclusions:
- Mitochondrial oxidative stress is a key factor in Parkinson's disease.
- Vitamin E therapy, specifically d-alpha-tocopherol enrichment of mitochondria, shows therapeutic potential for PD.
- Chronic high-dose vitamin E supplementation or administration may prevent or treat PD by protecting substantia nigra mitochondria.
More Related Videos
08:09Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
12:49Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
Published on: March 21, 2020
Related Concept Videos
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...